California Shows High Variability in Treatment Rates of Psoriasis
"By using our PatientFinder model of local epidemiology we found thatlocal prescription volumes in San Francisco and San Jose suggest that thesemetropolitan statistical areas have the highest treatment rates in the state,while Riverside and Bakersfield both have some of the lowest treatment rates,"states Jason LaBonte, Ph.D, vice president of new product development atDecision Resources.
The new analytics tools from Decision Resources entitled PatientFinder:Psoriasis also reveals that while the city of Los Angeles has a near-averagetreatment rate of 48 percent, its high prevalence of disease means that thereare still over 60,000 non-drug treated patients available in this metropolitanstatistical area.
Why Pharmaceutical Companies Need this Information
With the type of information included in PatientFinder, pharmaceuticalorganizations can identify the local markets that offer the greatestopportunity for their branded drug. Companies can identify markets that areunderserved and determine if they should increase direct-to-consumeradvertising, work with the local managed care organizations to increaseawareness of the disease and benefits of their drug or align salesrepresentatives to maximize market potential.
PatientFinder is the only healthcare analytics tool that assesses localmarkets for expansion opportunity by determining the number of insuredpatients in each territory who have the disease but are untreated.PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitanstatistical areas (MSAs) and provides:
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in marketresearch publications, advisory services and consulting designed to helpclients shape strategy, allocate resources and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. atwww.DecisionResourcesInc.com.
All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- Disease-specific prevalence numbers for each U.S. state and MSA -- Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA -- Unique analysis of the untreated population examined through a filter of prescription (Rx) benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory -- the true local measure of opportunity for pharmaceutical companies
SOURCE Decision Resources
You May Also Like